HPV Vaccination Strategies for Cervical Cancer Prevention
(IVaccinate Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial studies how well a multi-level health system-based intervention works in improving human papillomavirus (HPV) vaccine initiation and completion among children in health systems in four Appalachian states. Utilizing educational and promotional materials and electronic health record reminders, may improve the uptake of the HPV vaccine in children and young adults, ultimately preventing the development of cervical cancer.
Who Is on the Research Team?
Electra D. Paskett, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for healthcare providers and office staff in certain Appalachian states who care for patients aged 11-26, provide immunizations, and are involved in the vaccine process. Participants must be able to speak, read, and write English.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Early Intervention
Health systems receive educational materials, providers complete surveys and educational sessions, and patients receive educational materials and reminder letters for HPV vaccination.
Delayed Intervention
Health systems, providers, and patients receive usual care for 12 months, then receive the multi-level intervention as in the early intervention phase.
Follow-up
Participants are monitored for changes in HPV vaccination rates, knowledge, and attitudes of providers.
What Are the Treatments Tested in This Trial?
Interventions
- Educational Intervention
- HPV Vaccine
- Reminder
HPV Vaccine is already approved in United States, European Union, Canada, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator